Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
about
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
P2860
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I/II trial of cabazitaxe ...... ter docetaxel and abiraterone.
@en
Phase I/II trial of cabazitaxe ...... tion-resistant prostate cancer
@nl
type
label
Phase I/II trial of cabazitaxe ...... ter docetaxel and abiraterone.
@en
Phase I/II trial of cabazitaxe ...... tion-resistant prostate cancer
@nl
prefLabel
Phase I/II trial of cabazitaxe ...... ter docetaxel and abiraterone.
@en
Phase I/II trial of cabazitaxe ...... tion-resistant prostate cancer
@nl
P2093
P2860
P356
P1433
P1476
Phase I/II trial of cabazitaxe ...... ter docetaxel and abiraterone.
@en
P2093
D Bianchini
D P Petrylak
P2860
P356
10.1093/ANNONC/MDW441
P577
2016-10-18T00:00:00Z